Home
Clinical Trials
PUFAs in Preterm Infants

PUFAs in Preterm Infants

Last Updated: 2023-09-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-21

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The research endeavors to examine the critical composition of Polyunsaturated Fatty Acids (PUFAs) in premature infants across different gestational stages and under varying disease conditions, and delineate the metabolic attributes of PUFAs in premature infants and their interplay with the onset of diseases. This study anticipates furnishing a theoretical foundation for the rationalization of PUFAs supplementation in premature infants and for informing strategies related to disease prevention and management.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Enteral High-dose DHA Supplementation on Bronchopulmonary Dysplasia in Very Preterm Infants: a Collaborative Study

NCT05915806

Bronchopulmonary Dysplasia Child Development Neonatal and Perinatal Conditions

ACTIVE_NOT_RECRUITING NA

Physiologic Definition of Bronchopulmonary Dysplasia

NCT01223287

Infant, Newborn Infant, Low Birth Weight Infant, Small for Gestational Age +2 more

COMPLETED

Effect of a Parenteral Emulsion With Omega3 on Neonates With PPHN and CDH

NCT04031508

Pulmonary Hypertension of Newborn Diaphragm Defect

ENROLLING_BY_INVITATION PHASE2

Study of the Implication of Omega-3 Polyunsaturated Fatty Acids in Retinopathy of Prematurity in New-born Infants

NCT02820662

Retinopathy of Prematurity

COMPLETED NA

Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates

NCT01745510

Necrotizing Enterocolitis

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Necrotizing Enterocolitis Intraventricular Hemorrhage BPD - Bronchopulmonary Dysplasia Sepsis Periventricular Leukomalacia Patent Ductus Arteriosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Infants born between 24 and 36 weeks of gestational age who are admitted within 24 hours of birth, including both premature and full-term newborns.

\-

Exclusion Criteria

Infants with severe congenital developmental abnormalities, those requiring external supplementation of PUFAs in addition to standard intravenous nutrition and breastfeeding, and those with a severe prognosis indicating non-survival during their hospitalization.

\-

Eligible Sex

ALL

Accepts Healthy Volunteers